



2015: First in Human

GENERALVERSAMMLUNG 2016

GENERAL ASSEMBLY 2016

Disclaimer

This presentation contains statements about future developments and information from sources, which are deemed to be reliable by MetrioPharm AG. All statements in this presentation (including opinions, estimations, and assumptions), which are not historical facts, such as the future financial situation, the business strategy, plans, and objectives of the management, are statements with respect to the future development. These statements contain known and unknown risks, uncertainties, and other important factors that may cause the actual development to deviate substantially from the provided data relating to future developments or the results implied therein. These statements consider findings up to the time of preparation of the presentation and are based on numerous assumptions, which may turn out to be correct or wrong.

Although MetrioPharm AG is trying to make sure that the provided information and facts are correct and that the opinions and expectations are fair and appropriate, we are not liable for and do not guarantee the completeness, correctness, adequacy, or accuracy of any information and opinions contained herein.

MetrioPharm AG is reserving the right to make changes and amendments of the information provided herein without prior announcement. In addition, we hereby point out that the presentation may not contain all information about MetrioPharm AG and/or that this information may be incomplete or summarized.

2015: MOVING INTO CLINICAL STAGE OF DEVELOPMENT

DEFINING OUR STRATEGIC MARKET POSITION

MOVING CLINICAL DEVELOPMENT ALONG STRATEGY

CREATING VALUE

2015: MOVING INTO CLINICAL STAGE OF DEVELOPMENT

DEFINING OUR STRATEGIC MARKET POSITION

MOVING CLINICAL DEVELOPMENT ALONG STRATEGY





CREATING VALUE

Our Strategic Vision

Become the Leader in Therapies Against IMID

IMID ??

Immune-Mediated Inflammatory Diseases



- Lupus Erythematoses
- Ankylosing Spondylitis



- Behcet's disease
- Osteoarthritis
- Gout





MP1032

The First Safe and Effective Drug against IMIDs

Immune-Mediated Inflammatory Diseases

Europe + USA + J: 50 Million Patients

\$ 65 Billion Market Size



- Lupus Erythematoses
- Ankylosing Spondylitis



- Behcet's disease
- Osteoarthritis
- Gout

Target Market Segment

Pain Killers (NSAID)

- Aspirin
- Ibuprofen
- Diclofenac



Medical Need
+
Market Opportunity

SAFE & ORAL

Immune-suppressing Biologics

- Anti TNF
- Anti IL-6
- Anti IL-17



“Black-Box” Warnings

• Risk of serious infections
• Hospitalization or death
• Other malignancies,

MILD


MODERATE

SEVERE

Superior Safety Profile

USP of MP1032:

First IMiD Drug without Immune System Suppression

	Competitive Space	MP1032
	<ul style="list-style-type: none">• Methotrexate• Apremilast• DMF/Tecfidera• Anti-Cytokine Biologics	
GI side effects	+	-
Blood count effects	+	-
Risk of infections	+	-
Liver toxicity	+	-


2015: MOVING INTO CLINICAL STAGE OF DEVELOPMENT

DEFINING OUR STRATEGIC MARKET POSITION

MOVING CLINICAL DEVELOPMENT ALONG STRATEGY

CREATING VALUE

Development Plan On Track




Evidence for Safety

Pre-clinical

6 Week
Toxicology



up to
1000 mg/kg



 eurofins
BioPharma
Product Testing

 BIOSERVICE
SCIENTIFIC
LABORATORIES
GmbH


First in Human

2015
Phase I




from
50mg/day
Single dose

up to
600 mg/day
7 days




 SocraTec R&D
Concepts in Drug Research and Development

Development Plan On Track



Phase IIa Psoriasis

Indication:
Moderate-to-severe PSORIASIS
PASI Score > 10




MP1032
oral, 2x 100mg/day



Phase IIa Protocol

TIMELINE PER PATIENT



- **Primary endpoint: Safety and Tolerability**
- **Secondary endpoint: Therapeutic Effect**


2015: MOVING INTO CLINICAL STAGE OF DEVELOPMENT

DEFINING OUR STRATEGIC MARKET POSITION


MOVING CLINICAL DEVELOPMENT ALONG STRATEGY

CREATING VALUE

Clinical Proof-of-Concept Creates Substantial Value



Outlook



Summary

- Strategic Position as Leader in Safe IMiD Therapies
- Development Plan Reflects Strategic Goal
- Development Plan on Track
- Phase I Results Support Safety Claim
- Continued Value Creation through Clinical Data
 - Phase IIa Psoriasis
 - Phase IIa Tendinopathy
- MetrioPharm AG en Route towards a Fully Integrated Pharmaceutical Company



2015: First in Human

GENERALVERSAMMLUNG 2016

GENERAL ASSEMBLY 2016